Tariffs, Tech & Turnarounds: Where the Market’s Leadership Is Shifting

Tariffs landed, but markets shook them off.
Wall Street snapped its three-day skid with a broad rally Friday, signaling investors view Trump’s latest tariff barrage as sector-specific rather than systemic. The Dow climbed 0.65%, the S&P 500 gained 0.60%, and the Nasdaq rose 0.45%.

The big test was pharma. Trump announced a 100% tariff on branded drugs unless companies are actively building U.S. plants, plus levies on trucks, cabinets, and furniture. Instead of tanking, the sector rallied: Eli Lilly, Merck, and Pfizer all rose as investors concluded most majors already qualify for carveouts. Paccar surged 5% as tariffs favored domestic truckmakers, while Daimler Truck and Traton slipped in Europe.

Rates and currencies told a calmer story. The 10-year Treasury yield held around 4.18%, while the dollar index slipped slightly after a two-day surge. Oil steadied at $65 WTI and $69 Brent, with traders focused on Russian supply risk. Gold eased from highs, still trading above $3,775.

Investor Signal

Markets treated today’s tariff volley as noise, not narrative. That’s important: it shows traders still see policy shifts as redistributive across sectors rather than destructive to the whole market. The bar for systemic fear remains high. For portfolios, this pullback-and-bounce dynamic still favors selective rotation, into domestic beneficiaries of tariffs, into balance-sheet-backed AI plays, and into energy where supply shocks remain underpriced. Friday’s PCE will dictate whether dip-buyers lean in further or wait until October.

The market doesn’t care if you’re experienced or new… if you’re trading blind, it will take your money.

Adam Mesh, one of America’s most recognized traders, has seen it happen over and over. After selling his company for millions, he came out of retirement to share the strategy that protects him from getting wiped out.

In this free 43-minute training, Adam reveals how he’s generating income even in today’s unpredictable market.

Claim Your Free Training Before Your Next Trade.

Electronic Arts stock jumped double digits on reports that Silver Lake and Saudi Arabia’s Public Investment Fund are preparing a $50B take-private deal, one of the largest leveraged buyouts ever contemplated in tech and media.

The bid underscores how private equity and sovereign funds are circling content assets with recurring revenue, betting that gaming IP will remain resilient even as consumer spending wobbles. EA’s library of sports and franchise titles offers exactly that kind of stickiness.

Macro Watch: A buyout of this size would ripple beyond gaming. It signals that deep-pocketed funds are willing to absorb leverage risk to secure digital entertainment pipelines. That raises the floor under valuations for premium content firms, while spotlighting the scarcity of true platform assets.

Investor Signal

For investors, the takeaway is twofold: EA holders may see a near-term pop, but deal risk looms large if financing or political scrutiny stalls momentum. More broadly, peers like Take-Two and Ubisoft become more attractive as “next targets,” while publicly traded streaming and entertainment companies face pressure to prove their models before private capital prices them instead.

Fermi America is hitting the road with a $550M IPO, positioning itself as the REIT that will fuel the AI revolution, literally. The company’s Texas-scale plan includes 11 gigawatts of capacity by 2038, spanning natural gas, solar, batteries, and four large nuclear reactors branded the “Donald J. Trump Generating Plant.” If built, it would dwarf Hoover Dam and mark the largest U.S. nuclear build in decades.

The pitch is obvious: AI data centers are set to drive nearly half of U.S. electricity demand growth through 2030, and Fermi wants to sell itself as the purest public-market play on that theme. But the reality check is sobering. The company has no revenue, won’t see tenant cash flow until 2027, and admits losses will mount for years. Nuclear timelines are infamous, Westinghouse’s most recent builds came in $15B over budget and years late.

Macro Watch: Fermi’s value proposition is its vertical integration: land under a 99-year lease, pipeline access, equipment contracts, and political capital via co-founder Rick Perry. But execution risk is massive. Investors are betting more on the story, AI’s insatiable demand, than the balance sheet. In an environment where utilities are already in the political crosshairs for rising bills, Fermi’s promise of “behind the meter” independence could be both a selling point and a regulatory lightning rod.

Investor Signal

Fermi’s IPO is a pure sentiment trade. Early buyers are betting the “AI energy” label trumps execution risk in the short term, with valuation stretching far beyond fundamentals until late this decade. For energy portfolios, it raises the bar on incumbents like Vistra and Constellation, who can now be benchmarked against this growth narrative. For traders, expect high volatility: hype could drive outsized early gains, but delivery risk will stalk the name until shovels hit dirt.

Ethos Technologies filed for a Nasdaq debut under the ticker “LIFE” after reporting first-half 2025 revenue up 55% to $184M and net income up 64% to $31M. The San Francisco-based insurtech, backed by Sequoia, Accel, GV, and SoftBank, is positioning itself as the newest life-insurance platform in a hot IPO window.

The sector has been busy: half a dozen insurers have gone public since May, but results have diverged. Accelerant and Slide now trade below offer price, while American Integrity and Aspen delivered strong runs, with Aspen heading into a Sompo acquisition. Ethos will have to prove it belongs in the winners’ column.

Macro Watch: Ethos isn’t just an insurer, it’s a platform play. Policies activated on its marketplace rose 70% in H1, signaling product-market traction. Yet IPO investors are rightly cautious after seeing several peers underperform post-listing. The question is whether Ethos’ tech-enabled model can sustain margins in a space where underwriting cycles remain unforgiving.

Investor Signal

Insurance IPOs are offering traders a hot tape, but the after-market is littered with laggards. Ethos’ strong revenue growth and profitability set it apart from early-stage peers, but execution in public markets matters more than private pedigree. For portfolios, the angle is selective exposure: lean into profitable insurers with differentiated platforms, but expect dispersion to widen as the sector matures.

Elon Musk’s new AI model is blowing everyone’s mind.

It has been called “a game-changer in AI innovation”... “The future of AI”... And “a revolutionary leap forward.”

Tech legend and angel investor Jeff Brown believes this AI is so powerful that it will kill ChatGPT…

And make a lot of people rich in the process.

Click here to see the details before October 1st.

President Trump’s plan for a 100% tariff on branded drugs unless manufacturers are actively building U.S. plants rattled headlines Thursday night, but the market’s verdict was muted. Pharma giants from AstraZeneca to Novartis rushed to point out that cranes are already rising on their American sites, effectively shielding them from the new policy. Eli Lilly and others have even stockpiled key products in advance.

For smaller biotechs, though, the escape hatch isn’t so simple. Companies with only one or two therapies typically rely on overseas contract manufacturers, and they lack the capital to pivot quickly. For them, punitive tariffs risk erasing margins overnight, potentially forcing restructurings or distressed financing.

Macro Watch: This is less about near-term earnings at Pfizer or Novo Nordisk and more about market structure. Washington is drawing a line that rewards capital-heavy incumbents and punishes fragile innovators. It tilts incentives toward scale at the expense of dynamism, reinforcing the consolidation trend that has already defined biopharma M&A in recent years.

Investor Signal

Big pharma names look resilient here, many are already priced for political risk, and exemptions mean little near-term drag. But the weak link is the small and mid-cap biotech space, where tariffs could accelerate failures or fire-sale deals. For portfolios, that argues for leaning into scale (or domestic CDMOs who may pick up outsourced demand) while treating smaller names as high-beta policy trades rather than durable growth stories.

OpenAI just pushed out a salvo defining the next front in the AI war: compute, scale, and control. Over the past week, the company locked in marquee deals and public signals that are reshaping expectations for who controls the AI stack.

Among the highlights:

This is a pivot. AI was once a software arms race; now it’s infrastructure-first. Models matter, but only to the extent they can be deployed at scale, and scale depends on who owns the land, the electricity, the cooling, the pipelines, and the GPU corridors.

Macro Watch: We’re entering what could be called the “Compute Era” of AI, where industrial scale, capital intensity, and geographic control may define moat more than algorithmic edge. Smaller cloud-native AI teams will increasingly depend on rental compute from these vertically integrated titans. Think AWS, but for AI compute only, and fully owned, not rented.

Investor Signal:
The era of “software-only AI plays” is narrowing. Portfolios should tilt towards

And beware the flip side: pure cloud or model-centric names that compete for users but lack depth in the compute stack may suffer multiple compression in a world that increasingly prizes vertical integration.

Friday’s tape reinforced a key message: markets are no longer trading on broad panic but on selective repricing. Tariffs are a political weapon, but they’re being absorbed as sector reallocations, not macro shocks. Pharma proved resilient, trucks created clear winners and losers, and Costco showed that defensive retail doesn’t guarantee insulation from cost creep.

At the same time, Intel’s rebound, EA’s leveraged buyout buzz, and Ethos’s IPO filing highlight how capital markets are still rewarding growth stories with clear catalysts, even as rates hold firm near 4.2% and PCE looms. The new playbook is about differentiation: which companies can turn political headwinds into domestic tailwinds, and which can translate AI-fueled hype into cash flow.

For investors, the edge isn’t in chasing headlines but in recognizing when noise crystallizes into narrative. This week’s takeaway: the bull market is intact, but leadership is shifting beneath the surface. The portfolios that thrive will be those that rotate early, stay nimble, and price both policy risk and execution risk into every allocation.